This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of patients with adverse events (AEs) in Phase 1b
Timeframe: Up to approximately 3 years
Changes in vital signs in Phase 1b
Timeframe: Up to approximately 3 years
Changes in clinical laboratory test values in Phase 1b
Timeframe: Up to approximately 3 years
Dose Limiting Toxicities in Phase 1b
Timeframe: 21 days
Changes in ECGs in Phase 1b
Timeframe: Up to approximately 3 years
Overall Response Rate (ORR) in Phase 2
Timeframe: Up to approximately 3 years